The FDA gives an orphan drug designation to drug candidates that treat a disease that affects less than 200,000 persons in the United States.
The designation is designed to give financial incentives to drugmakers so that drugs for rare diseases will be developed. Those include:
- A 50% tax credit on clinical trial costs
- A break from paying Prescription Drug User Fee Act fees
- The all-important seven years of exclusive sales
Related Fool Articles
Recent Mentions on Fool.com
- Keep an Eye on AstraZeneca, Avanir, Bristol-Myers Squibb and VIVUS Today
- A Look Back at Immunomedics' Volatile but Rewarding 2013
- 3 Lessons Big Pharma Learned From BioMarin in 2013
- This Week in Biotech: Part 1
- Why Selling CROs Like Parexel May Be Short-Sighted
- Is the Celldex Offering a Reason to Be Scared?